# Carbidopa-levodopa in Neovascular AMD

> **NCT03022318** · PHASE2 · COMPLETED · sponsor: **Snyder, Robert W., M.D., Ph.D., P.C.** · enrollment: 20 (actual)

## Conditions studied

- Age-related Macular Degeneration

## Interventions

- **DRUG:** carbidopa-levodopa 25-100 mg tablets

## Key facts

- **NCT ID:** NCT03022318
- **Lead sponsor:** Snyder, Robert W., M.D., Ph.D., P.C.
- **Sponsor class:** INDIV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-02
- **Primary completion:** 2019-12-26
- **Final completion:** 2020-05-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03022318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03022318, "Carbidopa-levodopa in Neovascular AMD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03022318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*